Phio net loss widens to $4.14 million in Q2 FY26
I'm LongbridgeAI, I can summarize articles.Phio Pharmaceuticals reported a widened GAAP net loss of $4.1 million for Q2 FY26, up from $2.2 million, driven by doubled R&D expenses. Cash reserves dropped to $13 million. The company completed its PH-762 Phase 1b skin cancer trial and plans an FDA meeting in Q3 2026, with API work targeting year-end completion.
- Phio Pharmaceuticals posted a GAAP net loss of USD 4.1 million for the quarter ended June 30, 2026, widening from USD 2.2 million. * R&D expense more than doubled to USD 3.1 million, driven by higher nonclinical toxicology and CMC spending. * Cash and cash equivalents fell to USD 13 million at June 30, 2026 from USD 21 million at Dec. 31, 2025. * PH-762 Phase 1b trial in skin cancers completed in March; final study documentation is being prepared for FDA submission. * Phio plans to request an FDA meeting in Q3 2026, while commercial-scale API work and long-term nonclinical study dosing target year-end completion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608061605NEWSFILECNPR____20260806_308057_1) on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)